ISK-004

TNFRSF17; TNFSF13

ID Components Size (96 tests)
ISK-004-1 High-bind Plate 1plate
ISK-004-2 Human APRIL 10μg
ISK-004-3 Biotinylated Human BCMA 10μg
ISK-004-4 Anti-BCMA Neutralizing Antibody 40μg
ISK-004-5 Streptavidin-HRP 10μg
ISK-004-6 Coating Buffer 12mL
ISK-004-7 10xWashing Buffer 50mL
ISK-004-8 Blocking Buffer 50mL
ISK-004-9-A ELISA Femto Substrate A 6mL
ISK-004-9-B ELISA Femto Substrate B 6mL

BCMA (B cell maturation antigen), a member of the tumor necrosis factor receptor family. BCMA is mainly expressed on the surface of advanced B cells, short-lived proliferating plasmablasts and long-lived plasma cells, but not in naive B cells, CD34-positive hematopoietic stem cells and other normal tissue cells. With its specific expression ability, BCMA has become a good diagnostic marker and therapeutic target for multiple myeloma (MM).The main ligands of BCMA are BAFF and APRIL. When BCMA was combined with APRIL, the expression level of immune checkpoint was up-regulated to create an immunosuppressive bone marrow microenvironment. APRIL, as an important ligand of BCMA, is a member of the TNF(Tumor necrosis factor) receptor family (TNFSF-13A), which has 30% sequence homology with BAFF, another ligand of BCMA. But it has a higher affinity to interact with BCMA. It consists of 250 amino acids, of which 28 amino acids encode intracellular regions and 201 amino acids encode type II transmembrane proteins and their extracellular regions. The binding of APRIL to BCMA also induces both classical and non-classical NF-κB pathways, further promoting angiogenesis and metastasis, as well as tumor cell growth and proliferation.

96 tests

20-0.01μg/mL

This inhibitor screening Assay kit is designed to facilitate the identification and characterization of new BCMA pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human BCMA to immobilized human APRIL in a functional chemiluminescence assay. Briefly, we provide you with a human Biotinylated BCMA protein, a human APRIL protein, an anti-BCMA neutralizing antibody (as method verified Std.), and Streptavidin-HRP reagent.
Your experiment will include 4 simple steps:
a) Coat the plate with human APRIL.
b) Add your molecule of interest to the tests.
c) Add human BCMA-Biotin to bind the coated human APRIL.
d) Add Streptavidin-HRP followed by luminol.
Finally, the ability of your compound to inhibit APRIL: BCMA binding will be determined by comparing OD readings among different experimental groups.

This kit is developed for screening for inhibitors of human BCMA binding to human APRIL.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C.
The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

Serial dilutions of Anti-BCMA Neutralizing antibody (1:1 serial dilution, from 20 μg/mL to 0.01μg/mL) was added into Biotinylated BCMA: APRIL binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting.